Vascular Targeting Viral Therapy Augments Pd-L1 Checkpoint Blockade Anti-Tumor Activity

被引：0
|
作者：
Breitbart, Eyal [1 ]
Mendel, Itzhak [1 ]
Yacov, Niva [1 ]
机构：
[1] VBL Therapeut, Or Yehuda, Israel
来源：
MOLECULAR THERAPY | 2017年 / 25卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
585
引用
收藏
页码：270 / 271
页数：2
相关论文
共 50 条
  • [31] Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
    Sam, Johannes
    Colombetti, Sara
    Fauti, Tanja
    Roller, Andreas
    Biehl, Marlene
    Fahrni, Linda
    Nicolini, Valeria
    Perro, Mario
    Nayak, Tapan
    Bommer, Esther
    Schoenle, Anne
    Karagianni, Maria
    Le Clech, Marine
    Steinhoff, Nathalie
    Klein, Christian
    Umana, Pablo
    Bacac, Marina
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [32] Combination of MAPK inhibition with photothermal therapy synergistically augments the anti-tumor efficacy of immune checkpoint blockade
    Liu, Xiaowei
    Feng, Yanlin
    Xu, Jie
    Shi, Ying
    Yang, Jiqiao
    Zhang, Rongjie
    Song, Jinen
    Bai, Xin
    Wu, Xi
    Bao, Yu
    Luo, Ya
    Li, Huifang
    Chai, Li
    Gong, Changyang
    Wang, Yan
    Chen, Bo
    Hu, Jianping
    Fu, Yan
    Luo, Yongzhang
    Zhang, Haiyuan
    Shi, Hubing
    JOURNAL OF CONTROLLED RELEASE, 2021, 332 : 194 - 209
  • [33] Combination of the angiogenesis inhibitor lucitanib with immune checkpoint blockade augments anti-tumor activity in syngeneic models
    Dusek, Rachel
    Robillard, Liliane
    Harding, Thomas
    Simmons, Andrew
    Minh Nguyen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [34] Fc-silenced bispecific antibodies targeting PD-L1 and 4-1BB combine checkpoint blockade and T-cell co-stimulation to promote anti-tumor activity
    Muik, Alexander
    Altintas, Isil
    Gieseke, Friederike
    Salcedo, Theodora
    Burm, Saskia
    Diken, Mustafa
    Grunwitz, Christian
    Schuurhuis, Danita
    Kreiter, Sebastian
    Satijn, David
    Tureci, Ozlem
    Breij, Esther
    Sahin, Ugur
    Jure-Kunkel, Maria
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [35] Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1/PD-L1 interaction
    Zhang, Feng
    Yu, Qimeng
    Wu, Caiyun
    Sun, Shishi
    Wang, Yu
    Wang, Rui
    Chen, Zejie
    Zhang, Hua
    Xiong, Xuqiong
    Awadasseid, Annoor
    Rao, Guowu
    Zhao, Xiaoyin
    Zhang, Wen
    BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 111
  • [36] PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance
    van Gulijk, Mandy
    van Krimpen, Anneloes
    Schetters, Sjoerd
    Eterman, Mike
    van Elsas, Marit
    Mankor, Joanne
    Klaase, Larissa
    de Bruijn, Marjolein
    van Nimwegen, Menno
    van Tienhoven, Tim
    van Ijcken, Wilfred
    Boon, Louis
    van der Schoot, Johan
    Verdoes, Martijn
    Scheeren, Ferenc
    van der Burg, Sjoerd H.
    Lambrecht, Bart N.
    Stadhouders, Ralph
    Dammeijer, Floris
    Aerts, Joachim
    van Hall, Thorbald
    SCIENCE IMMUNOLOGY, 2023, 8 (83)
  • [37] Pheophorbide A-Mediated Photodynamic Therapy Potentiates Checkpoint Blockade Therapy of Tumor with Low PD-L1 Expression
    Tong, Qinli
    Xu, Jiaojiao
    Wu, Aihua
    Zhang, Chen
    Yang, Afeng
    Zhang, Sihang
    Lin, Hongzheng
    Lu, Wei
    PHARMACEUTICS, 2022, 14 (11)
  • [38] Targeting metabolic vulnerabilities of MDSCs to enhance the anti-tumor activity of PD-1 blockade in melanoma
    Zheng, B.
    Kim, S.
    Li, M.
    Trousil, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S137 - S137
  • [39] Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation
    Xu, Xiaoyan
    Xie, Tingxue
    Zhou, Mengxin
    Sun, Yaqin
    Wang, Fengqi
    Tian, Yanan
    Chen, Ziyan
    Xie, Yanqi
    Wu, Ronghai
    Cen, Xufeng
    Zhou, Jichun
    Hou, Tingjun
    Zhang, Lei
    Huang, Chaoyang
    Zhao, Qingwei
    Wang, Dongrui
    Xia, Hongguang
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [40] Relevance of host and tumor PD-L1 in PD-L1 pathway blockade
    Kryczek, Ilona
    Lin, Heng
    Wei, Shuang
    Green, Michael
    Zou, Weiping
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
12345